Asthma is one of the major growth areas in therapeutics and many new drugs are currently in development. These drugs include improvements of existing classes of drugs, notably once-daily inhaled ...

Although bronchial hyperresponsiveness to cholinergic agents is a main feature of asthma, the role of anticholinergic drugs in chronic asthma management has been largely underestimated.

A common inhaler drug used to treat tens of thousands of British asthma sufferers has been linked to a rare and potentially fatal hormone condition in children. New research, funded by the ...

The TGA has issued a requirement for new warnings to be provided with the drug montelukast, commonly used to treat asthma and hay fever.

The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology ...

A Wisconsin couple is suing Walgreens and a pharmacy benefits management company, alleging that their son died because he couldn't afford a sudden $500 spike in his asthma medication. Shanon and ...

It was originally approved in 2003 for the treatment of moderate to severe asthma. The drug was subsequently granted marketing authorization to treat chronic spontaneous urticaria and ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed ...

For many children diagnosed with asthma, pinpointing the particular ... Administration has approved several injectable or intravenous drugs for such patients. These counteract molecules that ...

Children who presented to the ED with severe asthma ... 5 mg/kg intravenous hydrocortisone as a bolus administered over 3 mins immediately followed by an infusion of the study drug administered ...

Australia's Therapeutic Goods Administration (TGA) recently issued a safety alert requiring extra warnings to be included with the asthma and hay fever drug montelukast. The warnings are for users ...